Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06590623

The Effect of Acute Exogenous Oral Ketone Supplementation on Immune Cells Function and Immune Cells Histone Β-hydroxybutyrylation

To conduct a single-arm pilot study to determine how acute ingestion of an exogenous ketone monoester supplement alters the histone lysine β-hydroxybutyrylation and immune function in healthy human monocytes and lymphocytes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of British Columbia Okanagan Campus

Kelowna, British Columbia, V1V1V7, Canada

Location status: Recruiting

Location contact

Alexis Marcotte-Chénard Postdoctoral fellow, Ph.D

CONTACT

[email protected]

250-807-9876

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over the age of 19
  • Able to fast overnight

Exclusion criteria

  • Being a competitive endurance athlete.
  • Following a ketogenic diet, low-calorie diet, periodic fasting regimen, or regularly consuming ketogenic supplements.
  • Being unable to travel to and from the university
  • Being pregnant.
  • Having been diagnosed with a chronic disorder of glucose or fat metabolism, including type 2 diabetes, chronic pancreatitis, or gallbladder disease
  • Being unable to read or communicate in English.

Treatment and study plan

Ketone Monoester (KE)

Dietary Supplement

Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.

Other names: Exogenous ketone

Primary outcomes

  1. β-hydroxybutyrylation of histone in human immune cells using Western blotting

    Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.

    The β-hydroxybutyrylation of histones in human monocytes and lymphocytes will be assessed before and 2 hours after the consumption of an exogenous ketone supplement. Protein samples will be collected from the cells, and the levels of histone β-hydroxybutyrylation will be quantified using Western blotting.

Secondary outcomes

  1. Change in beta-hydroxybutyrate concentration

    Time frame: Capillary beta-hydroxybutyrate will be measured before, 30, 60, 90, 120 and 180 minutes after the consumption of exogenous ketone supplement.

    Capillary beta-hydroxybutyrate concentration will be measured using FreeStyle Neo β ketone test before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.

  2. Change in glucose concentration

    Time frame: Capillary glucose concentration will be measured before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.

    Capillary glucose concentration will be measured using FreeStyle Neo glucose test before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.

  3. Change in blood pressure

    Time frame: Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.

    Systolic and diastolic blood pressure will be measured using an automatic blood pressure device before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.

  4. Change in resting heart rate

    Time frame: Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.

    Resting heart rate will be measured using continuous heart rate measurement (POLAR H10) before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.

  5. Alteration in immune cell functions

    Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.

    Immune cell functions in healthy individuals will be assessed using whole blood and monocyte cultures treated with lipopolysaccharide (with or without interleukin-10) and the subsequent measurement of cytokine secretion (e.g., TNF-a), both before and 2 hours after the ingestion of a ketone supplement.

  6. Monocytes and lymphocytes Immunophenotyping

    Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.

    Immunophenotyping of monocytes and lymphocytes will be conducted by assessing surface receptor expression using flow cytometry. Various antibodies will be used, including CD14, CD16, and TLR4 for monocytes, and CD4 and CD8 for lymphocytes, at baseline and 2 hours following the ingestion of a ketone supplement.

  7. Gastrointestinal Disturbance

    Time frame: Before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.

    Gastrointestinal disturbance will be measured using a 10-cm visual analogue scale to assess nausea, urge to vomit, bloating, belching, and cramps before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement. A higher score, closer to the right end of the 10-cm visual analogue scale, indicates greater gastrointestinal disturbance.

Study contacts

Contact information is provided by the study sponsor or research team.

Jonathan Little Principal Investigator, Professor Little, Ph.D

CONTACT

[email protected]

250-807-9876

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Registry information

Acronym: Acute_Ketone

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 19, 2024
Registry last updated
Mar 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.